is a Japanese

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympto ...

headquartered in

Tokyo Tokyo (; ja, 東京, , ), officially the Tokyo Metropolis ( ja, 東京都, label=none, ), is the capital and largest city of Japan. Formerly known as Edo, its metropolitan area () is the most populous in the world, with an estimated 37.468 ...

, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the

Tokyo Stock Exchange The , abbreviated as Tosho () or TSE/TYO, is a stock exchange located in Tokyo, Japan. It is the third largest stock exchange in the world by aggregate market capitalization of its listed companies, and the largest in Asia. It had 2,292 listed co ...

and is a member of the

Topix 100 , commonly known as TOPIX, along with the Nikkei 225, is an important stock market index for the Tokyo Stock Exchange (TSE) in Japan, tracking all domestic companies of the exchange's Prime market division. It is calculated and published by the T ...

and

Nikkei 225 The Nikkei 225, or , more commonly called the ''Nikkei'' or the ''Nikkei index'' (), is a stock market index for the Tokyo Stock Exchange (TSE). It has been calculated daily by the '' Nihon Keizai Shimbun'' (''The Nikkei'') newspaper since 1950 ...

stock index, stock indices.

History

Nihon Eisai Co. Ltd. was established in 1941. In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. The American subsidiary of the company, Eisai Inc., was established in 1995. On November 25, 1996, Eisai received Approved drug, approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer. Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson. In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals. In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing Monoclonal antibody therapy, therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases. In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion. This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio. In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel.

Locations

Eisai Co., Ltd. is based in

, Japan, while its American subsidiary Eisai Inc. is headquartered in Nutley, New Jersey. Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based. The company has manufacturing sites in Japan, North Carolina, North Carolina (USA), Maryland, Maryland (USA), Bogor, Bogor (Indonesia), Suzhou, Suzhou (China), Tainan, Tainan (Taiwan), Visakhapatnam, Visakhapatnam (India) and Hatfield, Hertfordshire, Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

Products

Some of the key products that Eisai produces or markets with partners include: *Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease *Actonel (risedronic acid) - Osteoporosis (Japan) *Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting *#Aricept, Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients *Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut syndrome, Lennox-Gastaut Syndrome *Belviq (lorcaserin) - Obesity *Dayvigo (lemborexant) - Insomnia *Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism *Fycompa (perampanel) - Partial-onset seizures *Halaven (eribulin) - Metastatic breast cancer *Iomeron (iomeprol) - Non-ionic contrast medium *Methylcobal (methylcobalamin) - Peripheral neuropathy *Myonal (eperisone) - Muscle relaxant *Selbex (teprenone) - Gastric ulcers and gastritis *Zonegran (zonisamide) - Partial-onset seizures *Gliadel Wafer (carmustine) - Treatment for Brain Tumors *Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer

Aricept

Aricept accounted for 40% of Eisai's revenue as of March 2010. The main competitor to Aricept is a generic formulation from Ranbaxy Laboratories, Ranbaxy Labs. Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.

References

External links